• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

    5/1/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMLX alert in real time by email

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its first quarter 2025 financial results on Thursday, May 8, 2025. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.

    To access the conference call, please dial +1 (800) 836-8184 (U.S. & Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations. The webcast will be archived and available for replay for 90 days following the event.

    About Amylyx Pharmaceuticals

    At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250501246589/en/

    Media

    Amylyx Media Team

    +1 (857) 799-7274

    [email protected]

    Investors

    Lindsey Allen

    Amylyx Pharmaceuticals, Inc.

    +1 (857) 320-6244

    [email protected]

    Get the next $AMLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMLX

    DatePrice TargetRatingAnalyst
    4/7/2025$7.00Neutral → Outperform
    Mizuho
    11/18/2024$3.00 → $11.00Neutral → Outperform
    Robert W. Baird
    10/23/2024$4.20 → $10.00Neutral → Buy
    BofA Securities
    3/18/2024$32.00 → $4.00Buy → Neutral
    Mizuho
    3/11/2024$27.00 → $4.00Outperform → Market Perform
    Leerink Partners
    3/11/2024$37.00 → $4.00Outperform → Neutral
    Robert W. Baird
    3/8/2024Buy → Neutral
    Goldman
    3/8/2024Outperform → In-line
    Evercore ISI
    More analyst ratings

    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

      Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation, underway in post-bariatric hypoglycemia (PBH); completion of recruitment expected in 2025, with topline data anticipated in first half of 2026 Data through Week 48 from the ongoing Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome to be presented at the Joint Congress of the European Society for Pediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) taking place from May 10-13 Phase 1 LUMINA trial of AMX0114, an investigational, potent antisense oligonucleotide targeting knockdown of calpain-2, underway in people livi

      5/8/25 7:00:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

      Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person. Bank of America 2025 Health Care Conference: Fireside chat on Tuesday, May 13, 2025, at 1:55 p.m. PT in Las Vegas, Nevada H.C. Wainwright 3rd Annual BioConnect Investor Conference: Corporate Presentation and Q&A on Tuesday, May 20, 2025, at 5:00 p.m. ET in New York City A live webcast of both presentations can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for repl

      5/7/25 8:00:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

      Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its first quarter 2025 financial results on Thursday, May 8, 2025. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (800) 836-8184 (U.S. & Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presenta

      5/1/25 9:00:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amylyx Pharmaceuticals Inc.

      SC 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

      11/12/24 1:22:53 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

      SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

      11/4/24 10:56:42 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

      SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

      10/25/24 5:38:25 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amylyx Pharmaceuticals upgraded by Mizuho with a new price target

      Mizuho upgraded Amylyx Pharmaceuticals from Neutral to Outperform and set a new price target of $7.00

      4/7/25 8:30:57 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Amylyx Pharmaceuticals from Neutral to Outperform and set a new price target of $11.00 from $3.00 previously

      11/18/24 7:31:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals upgraded by BofA Securities with a new price target

      BofA Securities upgraded Amylyx Pharmaceuticals from Neutral to Buy and set a new price target of $10.00 from $4.20 previously

      10/23/24 6:16:45 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zeiher Bernhardt G bought $37,005 worth of shares (10,000 units at $3.70) (SEC Form 4)

      4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

      3/24/25 4:15:37 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Frates James M bought $101,368 worth of shares (40,000 units at $2.53), increasing direct ownership by 21% to 233,464 units (SEC Form 4)

      4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

      9/16/24 5:30:37 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Firestone Karen bought $106,590 worth of shares (50,000 units at $2.13), increasing direct ownership by 1,000% to 55,000 units (SEC Form 4)

      4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

      9/9/24 4:05:06 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMLX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Amylyx Pharmaceuticals Inc.

      10-Q - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

      5/8/25 7:04:46 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

      5/8/25 7:01:20 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Amylyx Pharmaceuticals Inc.

      DEFA14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

      4/24/25 7:09:58 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMLX
    Financials

    Live finance-specific insights

    See more
    • Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

      Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its first quarter 2025 financial results on Thursday, May 8, 2025. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (800) 836-8184 (U.S. & Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presenta

      5/1/25 9:00:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

      Amylyx expects completion of recruitment for the LUCIDITY trial in 2025, with topline data in first half of 2026 Pivotal Phase 3 LUCIDITY trial evaluating avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation and Orphan Drug Designation; FDA-agreed-upon primary outcome of reduction in hypoglycemic events Avexitide has been previously evaluated in five post-bariatric hypoglycemia (PBH) clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant reductions in hypoglycemic events The Company continues to expect cash runway through the end of 2026 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "

      4/30/25 7:00:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

      - Amylyx expects early cohort data from LUMINA this year - AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the first participant has been dosed in LUMINA, the Company's Phase 1, multinational, randomized, double-blind, placebo-controlled, multiple ascending dose clinical trial of AMX0114, an investigational, potent antisense oligonucleotide (ASO) targeting calpain-2, in people living with amyotrophic lateral sclerosis (ALS). The Company continues to expect early cohort data from LUMINA in 2025. The L

      4/9/25 7:00:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursui

      4/8/24 6:24:09 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

      - Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx, Alexion, and ARIAD Pharmaceuticals Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the appointment of Camille L. Bedrosian, MD, as Chief Medical Officer ("CMO"). In this role, Dr. Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Dr. Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious disease

      11/28/23 7:00:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

      Amylyx will seek re-examination of its Conditional Marketing Authorisation Application Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name ALBRIOZA®, for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the European Union (EU). Today's update follows the Company's May 2023 announcement that the CHMP was trending toward a negative opinion.

      6/23/23 8:14:00 AM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Frates James M sold $37,806 worth of shares (10,896 units at $3.47), decreasing direct ownership by 4% to 290,988 units (SEC Form 4)

      4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

      4/2/25 5:22:59 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Bedrosian Camille L sold $43,082 worth of shares (12,425 units at $3.47), decreasing direct ownership by 6% to 194,375 units (SEC Form 4)

      4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

      4/2/25 5:14:24 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Mazzariello Gina sold $31,954 worth of shares (9,192 units at $3.48), decreasing direct ownership by 5% to 187,969 units (SEC Form 4)

      4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

      4/2/25 5:12:23 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

      For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

      9/29/22 5:02:14 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • September 2, 2022 - FDA Roundup: September 2, 2022

      For Immediate Release: September 02, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:   On Thursday, the FDA published the FDA Voices: “Using A Whole-Of-Governments Approach to Combating Illicit Health Products,” by Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA’s Europe Office. Crimi

      9/2/22 1:46:13 PM ET
      $AMLX
      Biotechnology: Pharmaceutical Preparations
      Health Care